Opportunity Overview
The Cancer Prevention and Research Institute of Texas has released RFA P-27.2-CSD, Cancer Screening and Early Detection, for FY 2027 Cycle 2. The program funds delivery of evidence-based clinical screening and diagnostic services for Texans who lack adequate access to cancer screening, early detection and related healthcare, with priority placed on populations and geographic areas disproportionately affected by cancer burden or barriers to care.
Funding and Key Dates
The online application opens September 16, 2026 at 7:00 AM Central Time in CPRIT’s new Grants Management Platform and closes December 8, 2026 at 5:00 PM Central Time. CPRIT anticipates review from January through April 2027, award notification in May 2027 and an anticipated project start of June 1, 2027.
- New project: up to $1.5 million for up to 3 years.
- Initial expansion: up to $2 million for up to 3 years.
- Maintenance expansion: up to $2.5 million for up to 5 years.
Funding maximums include direct and indirect costs. Indirect costs may not exceed 5% of the total award. CPRIT awards are reimbursement-based.
Eligible Applicants
The applicant must be a Texas-based entity, such as a community-based organization, health institution, government organization, public or private company, college or university, or academic health institution. The designated program director must have relevant education and management experience and reside in Texas during project performance. Collaborations are permitted and encouraged, but non-Texas collaborators are not eligible to receive CPRIT funds.
Required Clinical Model
The RFA supports evidence-based screening and early detection for breast, cervical, colorectal, liver and lung cancers under established national guidelines. Projects must include medically underserved areas, medically underserved populations and/or other priority populations in the defined service area. Comprehensive projects are expected to combine public and professional education, outreach, screening and diagnostic services, navigation into treatment for people with detected cancer or precancer, data tracking and sustainable system improvements.
CPRIT specifically recognizes service delivery through clinical facilities, community settings, mail-out models, mobile care and telehealth. Grant funds may support education services, clinical services, navigation, salary and benefits, project supplies, equipment, outreach and project travel. Funds may pay for diagnostic testing and navigation into treatment, but not cancer treatment itself; construction and renovation are not allowable.
Atlas Analysis
Atlas Opportunity Score: 98/100. This is a large, newly released, clinically oriented Texas prevention opportunity with explicit support for screening, diagnostics, navigation, equipment, mobile delivery and community partnerships. It is especially valuable for health systems, public-health organizations, community providers and regional partnerships serving rural or medically underserved Texans.
N9+ Direct Vendor Fit: 38/100, conditional Path B. Equipment and mobile/telehealth delivery are allowable, but the N9+ is not itself a mammography, cervical, colorectal, liver or lung cancer screening modality. A connected-exam role is defensible only when an eligible applicant demonstrates that it materially supports the approved screening workflow, access model, navigation or clinical follow-up and CPRIT accepts the cost. Atlas should not substitute N9+ for the evidence-based cancer screening and diagnostic services required by the RFA.
QC Healthcare Fit: 25/100, conditional. Clinical-service and telehealth workflows create a possible applicant-led physician-support role, but the RFA’s core purpose is cancer screening and diagnostic access rather than general physician coverage. Any QC role must be directly tied to an allowable project service and budget.
Next Action
Eligible Texas organizations should use the pre-opening period to define the target cancer burden and underserved service area, build the required screening-to-diagnosis-and-treatment-navigation continuum, confirm clinical and community partners, establish measurable service targets, identify any mobile or telehealth delivery model, document equipment needs, and activate or verify CPRIT GMP accounts. Submit through the new GMP between September 16 at 7:00 AM CT and December 8, 2026 at 5:00 PM CT.
Official RFA: CPRIT RFA P-27.2-CSD — Cancer Screening and Early Detection.
Funding portal: CPRIT Apply for Funding.